Tempus AI recently reported clinical validation results showing its Immune Profile Score (IPS) more accurately predicts outcomes for patients on immune checkpoint inhibitors than conventional ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the best Nancy Pelosi Stocks to buy in 2026. On January 27, Tempus AI, Inc. (NASDAQ:TEM) confirmed that its Immune Profile Score Test accurately predicts patient ...

Healthcare leaders are partnering with Tempus AI to bolster their development pipelines. Tempus' sales are expanding at a rapid pace. Tempus expects revenue to grow 83% year over year to $367 million ...

For 2025, the company reported revenue of around $1.27 billion, reflecting about 83% year-over-year growth, including roughly 30% organic growth excluding Ambry. By segment, Diagnostics revenue ...

Tempus AI is rated a strong buy for risk-tolerant investors, leveraging its vast proprietary healthcare data to drive precision medicine via AI and ML. TEM delivered 85% YoY revenue growth in Q3 2025, ...

Tempus AI TEM operates at the intersection of clinical genomics and AI-driven insights. Its testing and data products are gaining traction with providers and biopharma partners. With revenue up ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial-intelligence-powered programs for spotting the signs of cancer. The deal totals $81.25 million, ...

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, ...

Tempus AI is developing innovative AI solutions for the treatment of cancer and other diseases. Shares of Tempus AI plummeted after short-seller Spruce Point Capital Management released a critical ...

Tempus AI is a healthcare-oriented artificial intelligence company. Spruce Point Capital Management released a report critical of Tempus AI this week. Investors should exercise caution with Tempus AI ...